IDNA vs VHT

Key Takeaways

• IDNA is a thematic ETF targeting global companies in genomics, immunology, and bioengineering, while VHT provides broad exposure to the entire U.S. health care sector.
• IDNA holds approximately 50 stocks with a concentrated focus on innovative biopharmaceutical firms, whereas VHT maintains a diversified portfolio of over 420 holdings across pharmaceuticals, biotechnology, equipment, and services.
• IDNA carries a higher expense ratio of 0.47% compared to VHT's low-cost structure at 0.09%, reflecting its specialized strategy versus broad market replication.
• IDNA offers international diversification with significant exposure outside the United States, while VHT remains almost entirely U.S.-focused.
• Both ETFs are passively managed, but IDNA follows a rules-based thematic index and VHT tracks a comprehensive market-cap-weighted health care benchmark.
• Investors seeking targeted exposure to cutting-edge life sciences innovation may prefer IDNA, whereas those prioritizing broad sector diversification and cost efficiency may favor VHT.

Introduction

Health care remains a core sector for long-term investors due to demographic shifts, technological advances, and ongoing innovation in therapeutics. The iShares Genomics Immunology and Healthcare ETF (IDNA) and the Vanguard Health Care ETF (VHT) both provide equity exposure within this space yet pursue distinctly different strategies. IDNA delivers targeted access to genomics and immunology themes on a global basis, while VHT offers comprehensive coverage of the U.S. health care industry. These ETFs do not compete directly; instead, they serve as complementary or alternative tools depending on an investor's preference for thematic concentration versus broad sector representation.

iShares Genomics Immunology and Healthcare ETF (IDNA) Overview

The iShares Genomics Immunology and Healthcare ETF (IDNA) seeks to track the NYSE FactSet Global Genomics and Immuno Biopharma Index. This passive, rules-based fund invests in developed- and emerging-market companies positioned to benefit from long-term growth in genomics, immunology, and bioengineering. The ETF typically holds around 50 securities, resulting in a concentrated portfolio heavily weighted toward biotechnology and pharmaceutical innovators. Top holdings often include companies such as MRNA, TWST, and RVMD. Nearly all assets reside in the health care sector, with notable allocations to global names outside the United States. The expense ratio stands at 0.47%, and the fund rebalances periodically to maintain alignment with its underlying index.

Vanguard Health Care ETF (VHT) Overview

The Vanguard Health Care ETF (VHT) tracks the MSCI US Investable Market Health Care 25/50 Index through a passively managed, full-replication approach. This fund provides broad exposure to large-, mid-, and small-cap U.S. companies across the health care sector as classified by the Global Industry Classification Standard (GICS). It holds approximately 420 stocks, delivering diversified representation in pharmaceuticals, biotechnology, health care equipment, life sciences tools, managed care, and related sub-industries. Prominent holdings typically feature LLY, JNJ, ABBV, UNH, and MRK. The expense ratio is 0.09%, with quarterly rebalancing to match index weights. The structure emphasizes cost efficiency and comprehensive sector coverage within the United States.

Industry and Thematic Backdrop

The health care sector continues to attract capital amid aging populations, rising demand for innovative therapies, and advances in precision medicine. Genomics and immunology represent high-growth niches driven by breakthroughs in gene editing, mRNA technology, and targeted biologics. Regulatory developments around drug pricing and approval pathways, along with macroeconomic factors such as interest-rate expectations, influence capital flows into both broad health care and specialized biotech segments. Supply-chain resilience and global collaboration in life sciences remain key themes, while risks include clinical trial failures, patent expirations, and policy shifts affecting reimbursement.

Performance and Positioning Comparison

In recent market cycles, IDNA has exhibited higher volatility consistent with its concentrated exposure to early-stage and growth-oriented biotech names sensitive to clinical news and sentiment shifts. VHT has delivered more stable returns anchored by large-cap pharmaceutical and managed-care leaders with predictable cash flows. Sector rotation favoring defensive health care names or growth-oriented innovation has alternately benefited each fund's relative positioning. IDNA's global reach provides diversification against purely domestic policy risks, while VHT's scale and liquidity support efficient trading across market environments.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to discover additional opportunities aligned with your investment objectives.

Tickeron AI Verdict

Based on observable structural factors, Tickeron’s AI would likely assign a modest preference to VHT in the current environment. Its substantially lower expense ratio, greater diversification across hundreds of holdings, and established liquidity profile provide a more resilient foundation for broad health care exposure. While IDNA offers compelling access to high-conviction genomics and immunology themes with global reach, its higher cost and narrower focus introduce elevated concentration risk that may not suit all market regimes. Investors should weigh these trade-offs against individual objectives and risk tolerance.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations